

9 May 2024
ASX Announcement

Notice under ASX Listing Rule 3.10A

Tissue Repair Limited (ASX:TRP) (the Company) advises that, in accordance with ASX Listing Rule 3.10A, the following securities will be released from voluntary escrow on 18 May 2024.

Number of Securities	Type of Security	Escrow Release Date
4,656,830	Fully paid ordinary shares	18 May 2024
9,540,000	Options - Exercise price \$0.2055, Expire 30.12.2033	18 May 2024
1,600,000	Options - Exercise price \$1.15, Expire 15.11.2036	18 May 2024
2,500,000	Options - Exercise price \$0.3715, Expire 30.08.2034	18 May 2024

The release of the shares from voluntary escrow does not change the issued capital of the Company.

A summary of securities on issue is outlined in the table below:

Number of Securities	Details of Securities
60,464,843	Fully paid ordinary shares
1,700,000	Options – Exercise price \$0.2055, Expire 30.12.2033
800,000	Options – Exercise price \$0.3715, Expire 30.12.2033
630,000	Options – Exercise price \$0.3715, Expire 30.8.2034
1,265,000	Options – Exercise price \$0.3715, Expire 1.10.2034
3,919,292	Options – Exercise price \$1.15, Expire 15.11.2036
9,540,000	Options - Exercise price \$0.2055, Expire 30.12.2033
1,600,000	Options - Exercise price \$1.15, Expire 15.11.2036
2,500,000	Options - Exercise price \$0.3715, Expire 30.08.2034
392,753	Options - Exercise price \$1.15, Expire 27.09.2036
50,000	Options - Exercise price \$1.15, Expire 27.03.2036

For further information in relation to this release please contact Darryl Reed at darryl.reed@trtherapeutics.com 0419 557 663.

This announcement has been approved for release by TRP's Chair.

About Tissue Repair

Tissue Repair Limited (ASX:TRP) is an advanced biotechnology company developing second generation wound healing agents. The Company is a Phase 3 asset and is focusing on commencing phase 3 trials in chronic wounds for its lead drug candidate TR-987®, with a secondary focus on commercialising TR Pro+ a post procedure topical gel to accelerate healing and improve skin quality post any cosmetic procedure. The Company's longer-term strategy is to commercialise its propriety Glucoprime® API to treat a variety of wounds, skin and aesthetic conditions.



Tissue Repair Ltd

Level 10, 255 Pitt Street, Sydney, NSW 2000
ACN: 158 411 566